All the news

The persistence of a low viral load during the first twelve weeks of hepatitis C therapy is associated with an increased risk of relapse after the completion of treatment, investigators report in ...

Interim results presented at the Infectious Diseases Society of America (IDSA) conference yesterday show that 70.5% of 98 patients with HIV and hepatitis C who took the hepatitis C protease inhibitor (PI) drug ...

Up to 83% of individuals with chronic hepatitis C virus achieved a sustained virological response after receiving the investigational drug BMS-790052 in combination with pegylated interferon and ribavirin, results of a study presented ...

People with hepatitis C virus (HCV) genotype 1b respond better to boceprevir and are less likely to develop drug resistance than those with genotype 1a, according to study findings reported ...

The US Food and Drug Administration has approved a new hepatitis C drug telaprevir (Incivek), the agency announced today. Telaprevir is a direct-acting antiviral drug (an HCV protease inhibitor), licensed for use in combination ...

The European Medicines Agency has recommended marketing approval for Merck’s hepatitis C protease inhibitor boceprevir (Victrelis), the agency announced on May 20th. Boceprevir is the first direct-acting antiviral agent for hepatitis C to be ...

Even before new hepatitis C drugs come to market later this year, the vast array of hepatitis C antivirals currently in clinical trials is opening up new horizons for treatment of hepatitis ...

The experimental hepatitis C virus (HCV) protease inhibitor telaprevir, used with pegylated interferon plus ribavirin, produced good virological response in the first study of HIV/HCV co-infected individuals, according to interim data presented on Wednesday ...